{"id":"gemcitabine-clindamycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (gemcitabine)"},{"rate":null,"effect":"Nausea and vomiting (gemcitabine)"},{"rate":null,"effect":"Diarrhea (clindamycin)"},{"rate":null,"effect":"Pseudomembranous colitis (clindamycin)"}]},"_chembl":{"chemblId":"CHEMBL1200588","moleculeType":"Small molecule","molecularWeight":"461.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a deoxycytidine analog that is phosphorylated intracellularly and incorporated into DNA, causing chain termination and apoptosis in cancer cells. Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The rationale for combining these agents in a Phase 3 trial is unclear from available literature, though such combinations may target both malignant and microbial components in certain infections or explore immunomodulatory synergy.","oneSentence":"This combination pairs gemcitabine, a nucleoside analog that disrupts DNA synthesis in rapidly dividing cells, with clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:14.948Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown indication under Phase 3 evaluation by Prisma Health-Upstate"}]},"trialDetails":[{"nctId":"NCT03945357","phase":"PHASE3","title":"Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial)","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2019-05-15","conditions":"Ventral Hernia Repair","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemcitabine/ clindamycin","genericName":"Gemcitabine/ clindamycin","companyName":"Prisma Health-Upstate","companyId":"prisma-health-upstate","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs gemcitabine, a nucleoside analog that disrupts DNA synthesis in rapidly dividing cells, with clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis. Used for Unknown indication under Phase 3 evaluation by Prisma Health-Upstate.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}